Who Is Bluebird Botanicals? A Brand File on the Testing-Transparency Veteran
For over a decade, Bluebird set the standard for CBD lab transparency — a named lab, a public batch database, Eurofins-audited cGMP, and a founder who helped write the 2018 Farm Bill. Then, in January 2026, a public company bought it. A strong B, with the asterisk that its independent era just ended.
By The Kind Buds Desk · 12 min read · Updated 2026-06-29
Kind Buds Brand Transparency Score
A testing-transparency veteran with best-in-cohort lab disclosure: a named lab (Botanacor), a public batch/lot COA database, Eurofins-audited cGMP, B Corp status, and a founder with a deep, verifiable industry-leadership record. Pulled to a low B by the January 2026 cbdMD acquisition (which introduces ownership and go-forward opacity) and a few unconfirmed items — organic certifier, the post-deal leadership, and its 'triple-test' marketing.
An opinion grade from our transparent 6-pillar methodology, built on publicly sourced facts.
Best-in-class: a NAMED lab (Botanacor), a public batch/lot-number COA database with QR lookup, a full contaminant panel, Eurofins-audited cGMP (100% in 2019), and an independent Leafreport transparency score of 4.7/5. Minor deductions: no own in-house ISO-17025 lab, and a 'triple-test' claim we couldn't verify.
In-house CO2/ethanol/steam production in named Colorado facilities (Broomfield, Louisville), with Eurofins cGMP audits. Docked because the post-2026 cbdMD 'consolidated supply chain' clouds the go-forward manufacturing picture.
Colorado + partner farms, USDA-organic SKUs, and full-spectrum plus isolate options. Docked because the organic certifier isn't named and farm-level sourcing isn't fully documented.
Was a clean, founder-led, bootstrapped story — but the January 2026 all-equity asset sale to public company cbdMD, with thin disclosure (the founder's go-forward role unstated), introduces real ownership opacity. The deal is documented; the transition isn't.
Founder Brandon Beatty is publicly identified with a deep, verifiable record (US Hemp Roundtable EVP, AHPA trustee, helped draft 2018 Farm Bill language). Docked only because post-acquisition leadership is undisclosed.
No directly-attributable FDA letter, FTC action, lawsuit, or recall found, an A+ BBB, and strong independent reviews (Leafreport 4.1/5). Docked for an unclaimed/thin Trustpilot and a 2016 FDA letter that named a retailer (not Bluebird) and needs primary confirmation.
If you've ever read a guide on 'how to verify a CBD brand,' Bluebird Botanicals was probably the example of doing it right. Founded in Colorado in 2012, it built a reputation as a lab-transparency leader: a public batch database, a named testing lab, Eurofins-audited manufacturing, and a founder, Brandon Beatty, who helped write hemp legislation. We ran it through our six-pillar Brand Transparency Score and it earns a B (80/100) — and on testing alone, it scores like an A.
But there's a development most buyers haven't caught up to. In January 2026, Bluebird stopped being independent: a publicly traded company, cbdMD, acquired its assets in an all-stock deal. That's not inherently bad — but it ends the founder-led era that defined the brand, and the transition has been thinly disclosed (we don't even know the founder's go-forward role). So this file does something a little unusual: it grades a genuinely excellent transparency record while flagging that the company behind it just changed hands. Here's the receipts-first reality — including a couple of name-collision traps that snare almost everyone who writes about this brand.
The short version
- Our grade: B (80/100). An A-grade lab-transparency record, pulled to a low B by a just-completed ownership change.
- Best-in-class testing. A named lab (Botanacor), a public batch/lot COA database with QR lookup, a full panel, Eurofins-audited cGMP, B Corp status, and a Leafreport transparency score of 4.7/5.
- It was just acquired. In January 2026, public company cbdMD (NYSE American: YCBD) bought Bluebird's assets in an all-equity deal. The independent, founder-led era is over; the go-forward picture is thinly disclosed.
- A credentialed founder. Brandon Beatty (founder/CEO) is a US Hemp Roundtable EVP and AHPA trustee who helped draft 2018 Farm Bill language — strong people transparency. His post-deal role hasn't been disclosed.
- Two traps we avoided. 'Bluebird Bio' (a biotech) is a different company — its lawsuits aren't Bluebird Botanicals'. And the entity is Gaia Botanicals, LLC — not Gaia Herbs or Gaia, Inc.
| What the public record shows | |
|---|---|
| Brand | Bluebird Botanicals (bluebirdbotanicals.com) |
| Legal entity | Gaia Botanicals, LLC (Colorado; founded 2012) |
| Owner (since Jan 2026) | cbdMD, Inc. (NYSE American: YCBD) — acquired the assets |
| Founder | Brandon Beatty (US Hemp Roundtable EVP; AHPA trustee) |
| Manufacturing | In-house CO2/ethanol/steam; Broomfield & Louisville, CO |
| Hemp source | Colorado + partner farms; USDA-organic on select SKUs |
| Lab testing | Named lab (Botanacor); public batch/lot COA database + QR |
| Certifications | B Corp · cGMP (Eurofins-audited) · US Hemp Authority · Leaping Bunny |
| BBB rating | A+ (not accredited) — live profile |
| FDA / lawsuits / recalls | No direct FDA letter, lawsuit, or recall found (Bluebird ≠ Bluebird Bio) |
Bluebird Botanicals at a glance — the verified facts
The short version
Bluebird is the transparency veteran whose ownership just changed. On lab transparency, it's about as good as the category gets — a named lab, a public batch database, Eurofins-audited cGMP, a B Corp, and a founder with a real legislative footprint. If we graded only the bench, it would be an A.
What pulls it to a B is timing: in January 2026, public company cbdMD acquired Bluebird's assets, ending its independent era — and the transition has been thinly disclosed. That introduces ownership opacity our score is built to catch. The substance is excellent; the corporate moment is uncertain. We'll show the receipts, credit the openness, and disarm the name-collision traps (a biotech, two unrelated "Gaia" companies, a retailer's FDA letter) that snare almost everyone.
The acquisition that just ended Bluebird's independence
Here's the development to anchor everything else: in January 2026, cbdMD, Inc. — a publicly traded company (NYSE American: YCBD) — acquired substantially all the assets of Gaia Botanicals, LLC, the entity behind Bluebird, in an all-equity deal (restricted cbdMD shares plus an earnout; no cash; framed in the low-seven-figures). This is documented in cbdMD's press release and SEC filings.
The founder — and a genuinely strong people record
Bluebird's people transparency is one of its best pillars. Founder, chairman, and CEO Brandon Beatty started the company in 2012 (originally "Gaia Botanicals," selling rare herbs) and pivoted to hemp-CBD in 2013. His industry record is unusually verifiable: Executive Vice President of the U.S. Hemp Roundtable (Bluebird was a founding member), a seat on the AHPA Board of Trustees, co-founder of the Industrial Hemp Research Foundation, and a hand in drafting 2018 Farm Bill language. That's a real, checkable public footprint — not a stock "our team" page. The only deduction: with the cbdMD acquisition, Beatty's future role is undisclosed, so we can't say whether the person most associated with Bluebird's transparency is still steering it.
Lab testing — the flagship strength
This is why Bluebird earned its reputation:
- A public batch/lot COA database — enter a lot number (or scan the QR on the bottle) and pull the report.
- The lab is named — Botanacor Laboratories (Denver), among the first labs CDPHE-certified to test Colorado hemp.
- A full contaminant panel (cannabinoids, residual solvents, heavy metals, pesticides, microbials, toxins).
- Eurofins-audited cGMP — an ISO-accredited third party audited Bluebird's manufacturing, with a cited 100% rating in 2019.
- Independent validation — Leafreport scored Bluebird 4.1/5 overall and 4.7/5 on transparency, a top-tier mark.
The small caveats: the third-party testing is via Botanacor rather than an in-house ISO-17025 lab, and a "triple-test" slogan that circulates isn't something we could verify — so we don't repeat it. But the core program is the real thing, and it's what carries the grade.
The record: clean — and the name-collision minefield
Bluebird's record is clean, but verifying that required stepping around traps that catch most write-ups:
- No direct FDA warning letter to Bluebird/Gaia Botanicals. A 2016 letter named a retailer (Michigan Herbal Remedies) that sold a Bluebird product — Bluebird itself wasn't the recipient. We treat it as the retailer's letter, not Bluebird's.
- 'Bluebird Bio' is a different company. The securities lawsuits and FDA black-box noise that dominate a search for "Bluebird" belong to Bluebird Bio, Inc., a gene-therapy biotech — entirely unrelated. None of it is Bluebird Botanicals'.
- The entity is Gaia Botanicals, LLC — not Gaia Herbs (a North Carolina supplement brand) or Gaia, Inc. (a media/yoga company). Different companies, similar words.
- No FTC action, lawsuit, or recall found naming Bluebird/Gaia Botanicals.
- BBB A+, but not accredited on the live profile (despite some stale "accredited since 2019" claims), with strong independent reviews; its Trustpilot is thin/unclaimed, which we note as low-signal rather than a negative.
In short: a genuinely clean record, once you refuse the easy misattributions.
The bottom line
In our view, Bluebird Botanicals built one of the best transparency records in CBD — right as its independence ended. Named lab, public batch database, Eurofins-audited cGMP, a B Corp, and a founder who helped write the rules. On the merits that protect a buyer, it's excellent, and it earns a B (80/100).
The asterisk is real, though: the January 2026 cbdMD acquisition closed the founder-led chapter and the go-forward picture — leadership, facilities, whether the named-lab program continues — is thinly disclosed. That uncertainty is exactly what keeps an A-grade testing record at a low B. Our advice to a careful buyer: the COAs and the testing pedigree are trustworthy today, and you can still verify any batch — just know that the brand is mid-transition under a new public-company owner, and watch whether the transparency that defined it survives the integration. We'll update this file as the new structure becomes clear. The full methodology shows every point.
Questions, answered
Is Bluebird Botanicals legit?
Yes — and historically it's been one of the most transparent CBD brands in the country. Bluebird (legal entity Gaia Botanicals, LLC) posts a public batch/lot COA database, names its testing lab (Botanacor), holds Eurofins-audited cGMP and B Corp status, and earned a 4.7/5 transparency score from independent watchdog Leafreport, with a clean regulatory record. We grade it a B (80/100). The main caveat isn't quality — it's that in January 2026 a public company (cbdMD) acquired Bluebird's assets, ending its independent era, and the transition has been thinly disclosed.
Who owns Bluebird Botanicals now?
As of January 2026, Bluebird Botanicals is owned by cbdMD, Inc. (NYSE American: YCBD), a publicly traded company that acquired substantially all the assets of Gaia Botanicals, LLC (the Bluebird entity) in an all-equity deal. Before that, Bluebird was a founder-led, bootstrapped, Colorado company started by Brandon Beatty in 2012. Most older descriptions calling it 'independent' or 'family-owned' are now historical. The founder's go-forward role under cbdMD hasn't been disclosed, and cbdMD — which is itself covered in our Brand Files — has signaled it will consolidate supply chain and manufacturing without yet detailing what that means for Bluebird's Colorado operations.
Are Bluebird Botanicals' lab tests trustworthy?
Yes — this is the brand's signature strength. Bluebird maintains a public batch/lot-number database where you can pull a Certificate of Analysis (or scan the QR on the bottle), and it names its lab: Botanacor Laboratories, a CDPHE-certified Colorado lab. The panel is full (cannabinoids, solvents, heavy metals, pesticides, microbials, toxins), its manufacturing has been Eurofins-audited for cGMP (100% in 2019), and Leafreport scored its transparency 4.7/5. The minor caveats: testing is third-party via Botanacor rather than an in-house ISO-17025 lab, and a 'triple-test' marketing phrase that circulates isn't something we could verify.
Is Bluebird Botanicals the same as Bluebird Bio?
No — and this is the single most important correction. Bluebird Bio, Inc. is a gene-therapy biotech company, completely unrelated to Bluebird Botanicals the CBD brand. The securities lawsuits, investor alerts, and FDA black-box-warning news that show up when you search 'Bluebird' almost all belong to Bluebird Bio, not Bluebird Botanicals. We found no FDA warning letter, lawsuit, or recall directly attributable to Bluebird Botanicals (Gaia Botanicals, LLC). Separately, don't confuse the entity 'Gaia Botanicals' with Gaia Herbs or Gaia, Inc. — also different companies.
Is Bluebird Botanicals USDA organic?
On select products, yes. Bluebird offers USDA-organic SKUs (for example, an Organic CBD Oil made with USDA-certified-organic ingredients), alongside full-spectrum and isolate options sourced from Colorado and partner farms. The caveats: not every product is organic, and the specific USDA certifier isn't named in public sources, so treat the organic claim product-by-product and check the individual COA and label. Its broader credentials — B Corp, Eurofins-audited cGMP, US Hemp Authority, Leaping Bunny cruelty-free — are well-documented.
How did you research this, and is it fair to Bluebird?
Every claim is from a public source — Bluebird's own site (the lot-numbers/COA database, certifications, and memberships pages), the cbdMD acquisition press release and SEC filings, the Leafreport independent audit, the live BBB profile, and the FDA/FTC databases. We credited the genuine, best-in-cohort strengths (named lab, public batch database, Eurofins cGMP, a credentialed founder) and were careful to (a) time-stamp the January 2026 cbdMD acquisition, (b) keep Bluebird Bio's unrelated litigation out, and (c) attribute the 2016 FDA letter to the retailer that received it, not to Bluebird. The B reflects an excellent transparency record held to a low B by a just-completed ownership change with thin go-forward disclosure. As the new structure clarifies, we'll update the file.
Filed under Field Notes